Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $41
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $75
Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $70
RBC Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $60
Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $80
Ionis Pharmaceuticals Inc (IONS) (Q3 2026) Earnings Call Highlights: DAWNZERA Momentum and ...
Ionis Pharmaceuticals: Q3 Triggers The Latest Selloff On Tryngolza Disappointment
Loading...